EUVIMEDEUVIMED entdecken
Crossref

Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence

Rowena Brook, Vincent Lu, Prahlad Ho, Hui Yin Lim, Julie Wang

Seminars in Thrombosis and Hemostasis · 19.11.2026

DOI: 10.1055/a-2982-1789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 19.11.2026. Verfasst von Rowena Brook und 4 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Gefördert von: University of Melbourne, Northern Health Foundation, Australia, Bristol Myers Squibb–Pfizer Alliance, Australia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following venous thromboembolism (VTE), predictive biomarker testing for risk assessment is hampered by the presence of anticoagulation. This study aims to remove in vitro interference caused by direct oral anticoagulants (DOACs) with DOAC-Stop, enabling thrombin generation testing during anticoagulation. Platelet-poor plasma was collected approximately 3 months after VTE diagnosis from adults who were therapeutically anticoagulated with apixaban or rivaroxaban. Thrombin generation testing was performed using ST-Genesia ThromboScreen, following use of DOAC-Stop. A total of 251 patients were included (mean age 55.4 years, 54.2% male). Patients with thrombophilia and/or family history of VTE demonstrated hypercoagulable thrombin generation parameters. A total of 165 patients (65.7%) were classified as clinically “high risk,” defined as one or more of unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT), family history of VTE, personal prior history of VTE, and hereditary thrombophilia, with remaining cases considered “low-risk” VTE. The “high-risk” group demonstrated increased peak height, endogenous thrombin potential, and velocity index compared with the “low-risk” cohort. About 52.2% (n = 131/251) of all patients subsequently ceased anticoagulation, with five episodes of unprovoked recurrence occurring within 1 year of cessation. These patients had higher median peak height (139.4 vs. 104.6%, p = 0.043, percentile difference − 34.8, 95% confidence interval (CI): [− 68.4, − 1.81]) and ETP (119.5 vs. 103.7%, p = 0.006, percentile difference: − 27.5, 95% CI: [− 43.5, − 11.3]) without thrombomodulin. This study provides evidence that thrombin generation testing after DOAC-Stop can identify hypercoagulable VTE patients without interrupting anticoagulation. Thrombin generation was increased in several groups with clinical risk factors associated with hypercoagulability. Key thrombin generation parameters were increased and associated with unprovoked VTE recurrence in patients who later stopped anticoagulation. Larger confirmatory studies are required.

Förderung

  • University of Melbourne
  • Northern Health Foundation, Australia
  • Bristol Myers Squibb–Pfizer Alliance, Australia
  • National Health and Medical Research Council
  • Stago, Australia
  • National Heart Foundation of Australia

Zitieren

APA

Brook, R., Lu, V., Ho, P., Lim, H. Y., & Wang, J. (2026). Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2982-1789

Vancouver

Brook R, Lu V, Ho P, Lim HY, Wang J. Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2982-1789

BibTeX
@article{Brook2026,
  author = {Brook, Rowena and Lu, Vincent and Ho, Prahlad and Lim, Hui Yin and Wang, Julie},
  title = {Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  doi = {10.1055/a-2982-1789}
}
Kostenlos starten →